Fred Eshelman, Chapel Hill graduate and founder of Pharmaceutical Product Development, returns $100m to his alma mater.

Returning backers included Baxter Ventures, Takeda Ventures and Lundbeck, as Naurex, which is developing treatments for depression, boosted its total funding to $135m.

Johnson & Johnson-backed Direct Flow Medical raised $32m, including $15m in debt from PDL BioPharma, as it seeks to advance its transcatheter device.

Mayo Clinic-backed Seres has raised its third funding round in just over a year and could go public as early as next year.

Life sciences firm Elekta signs agreement with Toronto spin-out Acumyn for its quality management system.